Abstract
Platelets play an important role in both normal hemostasis and pathological thrombus formation. The key role of platelets in thrombosis is highlighted by the clinical benefit of treatment with antiplatelet drugs. Aspirin, either alone or in combination with clopidogrel in high-risk patients, is the most widely used antiplatelet agent. However, there is an individual response to these agents that may reduce the cardiovascular protection in patients who achieve a lower antiplatelet effect. Recently, P2Y12 receptor antagonists more potent than clopidogrel (e.g., prasugrel and ticagrelor) have been approved for patients with acute coronary syndromes and those undergoing percutaneous coronary interventions; these drugs provide greater platelet inhibition than clopidogrel. However, the increased effectiveness of these treatments has underscored the importance of carefully balancing the risks of ischemia and bleeding to achieve the best clinical outcomes. The increased knowledge of the molecular mechanisms of platelet activation has prompted a search for novel pharmacological targets for the inhibition of platelet reactivity. This article reviews the molecular mechanisms of action and limitations of use of current and emerging antiplatelet agents for treatment of cardiovascular disease.
Keywords: Aspirin resistance, clopidogrel, GPIIbIIIa antagonists, PAR-1 antagonists, phosphodiesterase inhibitors, prasugrel, thromboxane receptor antagonists, ticagrelor.
Current Vascular Pharmacology
Title:Pharmacological Inhibition of Platelet Reactivity. Clinical and Pharmacodynamic Effects
Volume: 11 Issue: 4
Author(s): Juana Valles, Antonio Moscardo, Isabel Madrid and Maria Teresa Santos
Affiliation:
Keywords: Aspirin resistance, clopidogrel, GPIIbIIIa antagonists, PAR-1 antagonists, phosphodiesterase inhibitors, prasugrel, thromboxane receptor antagonists, ticagrelor.
Abstract: Platelets play an important role in both normal hemostasis and pathological thrombus formation. The key role of platelets in thrombosis is highlighted by the clinical benefit of treatment with antiplatelet drugs. Aspirin, either alone or in combination with clopidogrel in high-risk patients, is the most widely used antiplatelet agent. However, there is an individual response to these agents that may reduce the cardiovascular protection in patients who achieve a lower antiplatelet effect. Recently, P2Y12 receptor antagonists more potent than clopidogrel (e.g., prasugrel and ticagrelor) have been approved for patients with acute coronary syndromes and those undergoing percutaneous coronary interventions; these drugs provide greater platelet inhibition than clopidogrel. However, the increased effectiveness of these treatments has underscored the importance of carefully balancing the risks of ischemia and bleeding to achieve the best clinical outcomes. The increased knowledge of the molecular mechanisms of platelet activation has prompted a search for novel pharmacological targets for the inhibition of platelet reactivity. This article reviews the molecular mechanisms of action and limitations of use of current and emerging antiplatelet agents for treatment of cardiovascular disease.
Export Options
About this article
Cite this article as:
Valles Juana, Moscardo Antonio, Madrid Isabel and Santos Teresa Maria, Pharmacological Inhibition of Platelet Reactivity. Clinical and Pharmacodynamic Effects, Current Vascular Pharmacology 2013; 11 (4) . https://dx.doi.org/10.2174/1570161111311040007
DOI https://dx.doi.org/10.2174/1570161111311040007 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Nanoceuticals as an Emerging Field: Current Status and Future Prospective
Current Nutrition & Food Science Vitamin D status in coronary artery disease: association with IL-35 and TGF-β1 and disease severity
Endocrine, Metabolic & Immune Disorders - Drug Targets Drug-Induced QTc Interval Prolongation: A Multicenter Study to Detect Drugs and Clinical Factors Involved in Every Day Practice
Current Drug Safety Gestational Diabetes and the Metabolic Syndrome: Can Obesity and Small, Dense Low Density Lipoproteins be Key Mediators of this Association?
Current Pharmaceutical Biotechnology Editorial: New Insights into a Classical Pathway: Key Roles of the Mevalonate Cascade in Different Diseases (Part II)
Current Molecular Pharmacology Novel Anti-Arrhythmic Drugs for Atrial Fibrillation Management
Current Vascular Pharmacology Second-Generation Antipsychotic Agents: A Review of Safety Profiles
Current Psychiatry Reviews The Role of the Novel Adipocyte-Derived Protein Adiponectin in Human Disease: An Update
Mini-Reviews in Medicinal Chemistry Concepts for Nano-delivery of Therapeutic Immunomodulatory Agents
Current Bionanotechnology (Discontinued) Population-based Study of Risk Polymorphisms Associated with Vascular Disorders and Dementia
Current Genomics Surgical Ventricular Restoration to Reverse Left Ventricular Remodeling
Current Cardiology Reviews P2X7 Receptors: Channels, Pores and More
CNS & Neurological Disorders - Drug Targets Editorial: Statins and Tissue Plasminogen Activator for Stroke: A Beneficial Combination?
Current Vascular Pharmacology Pathophysiology of Diabetic Dyslipidaemia
Current Vascular Pharmacology The Perfect Storm: A Rheumatologist's Point of View on COVID-19 Infection
Current Rheumatology Reviews SIRT1 as a Novel Potential Treatment Target for Vascular Aging and Age-Related Vascular Diseases
Current Molecular Medicine Optimized Turmeric Extracts have Potent Anti-Amyloidogenic Effects
Current Alzheimer Research Stroke in Women - Oral Contraception, Pregnancy, and Hormone Replacement Therapy
Current Vascular Pharmacology Olive Oil and Haemostasis
Current Nutrition & Food Science Inflammatory Mechanisms and Redox Status in Periodontal and Cardiometabolic Diseases: Effects of Adjunctive Nutritional Antioxidants and Statins
Infectious Disorders - Drug Targets